<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259558</url>
  </required_header>
  <id_info>
    <org_study_id>PC3</org_study_id>
    <secondary_id>EC - L069/2003</secondary_id>
    <secondary_id>BFARM - 402 2919</secondary_id>
    <nct_id>NCT00259558</nct_id>
  </id_info>
  <brief_title>Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis</brief_title>
  <official_title>Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Wolfgang Stremmel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dietmar Hopp Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the optimal dose of retarded release Phosphatidylcholine
      in the most severe form of ulcerative colitis.

      The hypothesis is that ulcerative colitis (UC) is caused by a barrier dysfunction of the
      colonic mucus layer. The background of the study is the finding, that the phosphatidylcholine
      (PC) content of the colonic mucus is strongly reduced in UC compared to healthy controls and
      patients with CrohnÂ´s disease. The content was meuasured in non-inflamed areas of the colon
      in UC. Thus, we evaluate whether a substitution of colonic PC is an effective method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: prospective, randomized, double-blind, dose-finding study with retarded
      phosphatidylcholine.

      Population: 10 patients per dose group (6 doses) - 60 patients Remark: this includes to
      historic groups from another study Inclusion criteria: Ulcerative Pancolitis with chronic
      active course and a clinical index (Rachmilewitz) over 7 and more, endoscopic index of at
      least 7 or more. No systemic steroids or immunosuppressants since 4 weeks.

      Exclusion criteria: Pregnancy &amp; fulminant course
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in clinical activity index (Rachmilewitz).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary end points include &gt;50% changes in clinical and endoscopic activity index (EAI).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology and life quality are reported descriptively.</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>retarded release phosphatidylcholine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic active ulcerative pancolitis

          -  course more than 4 months

          -  clinical index rachmilewitz 7 or more

          -  endoskopic index 7 or more

        Exclusion Criteria:

          -  steroids in the last 4 weeks

          -  immunosuppressants in the last 4 weeks

          -  use of topical klymsa

          -  pregnancy

          -  fulminant course

          -  infectious colitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Stremmel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Hospital Unversity Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005 Jul;54(7):966-71.</citation>
    <PMID>15951544</PMID>
  </reference>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2005</study_first_submitted>
  <study_first_submitted_qc>November 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>February 7, 2007</last_update_submitted>
  <last_update_submitted_qc>February 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2007</last_update_posted>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Dose Finding</keyword>
  <keyword>Phosphatidylcholine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

